The company is establishing commercial production capabilities to fuel plans to launch autologous CAR-T cell therapies in China.

Following through with its sizable investment commitment in China, AstraZeneca on Thursday unveiled plans to build a commercial cell therapy manufacturing base and an innovation center dedicated to | ...

Everyone’s favorite bracket challenge has returned. That’s right—it’s time once again for Fierce Pharma Marketing’s annual ...

GRANTS PASS, OR / ACCESS Newswire / March 16, 2026 / Venture capitalist and biotech entrepreneur Andrew Hamilton, through his investment firm Pale Horse Capital, has acquired the premium ...

BEIJING, March 18 (Xinhua) -- With China's new five-year blueprint ushering in fresh commercial opportunities driven by tech ...

UK pharma major AstraZeneca’s majority owned Indian subsidiary, today announced that Central Drugs Standard Control Organization (CDSCO) has approved an additional indication for durvalumab solution ...

GRANTS PASS, OR / ACCESS Newswire / March 16, 2026 / Venture capitalist and biotech entrepreneur Andrew Hamilton, through his ...

British drugmaker AstraZeneca Plc AZN has emerged as the leading contender to acquire French biotech Abivax SA ABVX, following the company's dramatic valuation surge after strong clinical progress ...

AstraZeneca’s Imfinzi (durvalumab) in combination with standard-of-care FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, and docetaxel) has been approved in the European Union (EU) for the ...

XOMA Royalty (NASDAQ:XOMA) executives used the company’s 2025 financial results call to emphasize a year of portfolio ...

Guardant Health (NASDAQ:GH) executives used a Barclays discussion to outline growth drivers across treatment selection, ...

InfoComm 2026 will showcase the technologies, strategies and real-world deployments shaping the next era of conferencing and ...